Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide with nilotinib vs temozolomide alone in newly diagnosed glioblastoma multiforme
IRCT20140120016280N6Phase 2Completed
- Sponsor
- NIMAD
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of temozolomide and nilotinib in glioblastoma (GBM) (2 arms), sponsored by NIMAD. Started Mar 2022; status: completed.
02
Drugs
temozolomidenilotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on IRCT20140120016280N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140120016280N6.